Company: ERAS
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103868
Chunk: 49

Company: Erasca, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 49
---
 non-employeedirector compensation set forth in the 2021 Plan. Our Board or its authorized committee may modify the non-employeedirector compensation program from time to time in the exercise of its business judgment, taking into account such factors, circumstances and considerations as it shall deem relevant from time to time, subject to the annual limit on non-employeedirector compensation set forth in the 2021 Plan (which limits will not apply to any non-employeedirector that serves in any additional capacity with the company for 31

which he or she receives compensation or any compensation paid to any non-employeedirector prior to the calendar year following the calendar year in which this offering occurs). As provided in the 2021 Plan, our Board or its authorized committee may make exceptions to this limit for individual non-employeedirectors in extraordinary circumstances, as the Board or its authorized committee may determine in its discretion, provided that the non-employeedirector receiving such additional compensation may not participate in the decision to award such compensation or in other compensation decisions involving non-employeedirectors. Employment arrangements with Dr. Varney We have entered into an employment letter agreement with Dr. Varney, which governs the terms of his employment with us as our Chair of R&D. In this role, Dr. Varney also acts as a senior advisor to our Chief Executive Officer. Pursuant to his letter agreement, Dr. Varney is entitled to an annual base salary. In February 2025, Dr. Varney received a base salary increase from $86,400 to $89,900, effective November 1, 2024. Dr. Varney’s employment is at-will. In addition, in June 2024, Dr. Varney was granted an option to purchase 60,000 shares of our common stock under our 2021 Plan. The option is eligible to vest in full on June 20, 2025, subject to his continuous service through such date. Dr. Varney also serves on our scientific advisory board, or SAB, but does not receive any additional cash compensation for such service. Pursuant to his scientific advisory board agreement with Dr. Varney, which governs the terms of his retention with us as a SAB member and as a consultant, Dr. Varney is subject to a non-competitioncovenant during the term of his service with us, as well as one-yearpost- termination non-solicitationof employees and consultants covenant and a perpetual confidentiality covenant,